HomeMACK • NASDAQ
add
Merrimack Pharmaceuticals Inc
Previous close
$14.73
Day range
$14.72 - $14.75
Year range
$11.53 - $15.89
Market cap
214.34M USD
Avg Volume
116.37K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Revenue | — | — |
Operating expense | 490.00K | -19.28% |
Net income | -240.00K | 51.22% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | — | — |
Effective tax rate | -5.26% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 18.88M | -2.90% |
Total assets | 19.19M | -3.27% |
Total liabilities | 441.00K | -25.13% |
Total equity | 18.75M | — |
Shares outstanding | 14.52M | — |
Price to book | 11.24 | — |
Return on assets | -6.37% | — |
Return on capital | -6.52% | — |
Cash Flow
Net change in cash
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Net income | -240.00K | 51.22% |
Cash from operations | -295.00K | -59.46% |
Cash from investing | 68.00K | — |
Cash from financing | 133.00K | -97.96% |
Net change in cash | -94.00K | -101.48% |
Free cash flow | -229.25K | -212.44% |
About
Merrimack Pharmaceuticals is a pharmaceutical company based in Cambridge, Massachusetts, United States. They specialize in developing drugs for the treatment of cancer.
Merrimack's first FDA-approved drug was approved in 2015; Onivyde, a liposome encapsulated version of irinotecan is used for treating pancreatic adenocarcinoma. It was approved for use in the European Union the following year. Wikipedia
Founded
2000
Website
Employees
27